EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, today announced the appointment of Corleen Roche as Chief Financial Officer. Ms. Roche is a highly accomplished CFO with an extensive background in corporate finance and strategy in the biopharmaceutical industry, and served most recently as the US CFO for Biogen.
“On behalf of the entire company, I am pleased to welcome Corleen to Immunome and look forward to partnering with her as we grow the company together,” said Purnanand Sarma, Ph.D., President and CEO of Immunome. “As we continue our rapid growth into a clinical-stage company, Corleen’s significant experience will be integral to our success in furthering our promising portfolio of development candidates. Corleen brings with her a deep understanding of financial strategy, capital markets, and business development and I am thrilled that Immunome will benefit from her business and financial acumen.”
“I would like to thank Sarma and the Immunome team for welcoming me to the company,” said Corleen Roche, Chief Financial Officer of Immunome. “I was drawn to Immunome by the promise of the company’s proprietary human memory B cell platform, as well as the quality of the team overseeing its deployment. I look forward to leveraging my financial expertise to progress the company’s development plans and help Immunome achieve its full potential.”
Corleen Roche is a corporate finance and business strategist with extensive executive experience in the biopharmaceutical industry. Prior to her most recent role as the U.S. CFO for Biogen, Ms. Roche was a CFO at various biopharmaceutical companies including Sandoz, IoGenetics Inc, and Wyeth Pharmaceuticals.
Ms. Roche received a Bachelor of Science in Accountancy from Villanova University.
Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company’s initial focus is on developing therapeutics to treat oncology and infectious diseases, including COVID-19. Immunome’s proprietary discovery engine identifies novel therapeutic antibodies and their targets by leveraging the highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease. For more information, please visit www.immunome.com.
This press release includes certain disclosures that contain “forward-looking statements” intended to qualify for the “safe harbor” from liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding Immunome’s beliefs and expectations regarding the advancement of its oncology and COVID-19 therapeutic antibody programs, execution of its clinical and strategic plans, anticipated upcoming milestones for IMM-BCP-01 and IMM‐ONC‐01, including expectations regarding therapeutic potential and benefits thereof, and IND filings. Forward-looking statements may be identified by the words “anticipate,” believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “may,” “will,” “could,” “should,” “seek,” “potential” and similar expressions. Forward-looking statements are based on Immunome’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the impact of the COVID-19 pandemic on Immunome’s business, operations, strategy, goals and anticipated milestones; Immunome’s ability to execute on its strategy including with respect to the timing of its R&D efforts, IND filings, initiation of clinical studies and other anticipated milestones; the timing and effectiveness of any antibody therapeutics which may be developed by Immunome; Immunome’s ability to fund operations; and the additional risks and uncertainties set forth more fully under the caption “Risk Factors” in Immunome’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 25, 2021, and elsewhere in Immunome’s filings and reports with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Immunome undertakes no duty to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.